![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amarin Corp | LSE:AMRN | London | Ordinary Share | GB00B29VL935 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 92.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:2389B Amarin Corporation Plc 31 July 2007 AMARIN CORPORATION PLC LONDON, United Kingdom, July 31, 2007 Amarin Corporation plc (the "Company") has made a block listing application to the London Stock Exchange and the Irish Stock Exchange in respect of 820,343 ordinary shares of #0.05 each ("Ordinary Shares") in the capital of the Company to be admitted to trading on AIM and IEX, of which 175,000 Ordinary Shares are issuable from time to time following the exercise of warrants issued to Neurostat Pharmaceuticals Inc on April 27, 2007, 615,343 Ordinary Shares are issuable from time to time following the exercise of warrants issued in a registered direct offering of the Company's Ordinary Shares on June 1, 2007, and 30,000 Ordinary Shares are issuable from time to time following the exercise of warrants issued to Proseed Capital Holdings CVA on June 21, 2007. About Amarin Amarin is committed to improving the lives of patients suffering from diseases of the central nervous system. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs. Amarin's core development pipeline includes, in addition to Miraxion for several therapeutic indications, four other key development programs in Parkinson's disease, epilepsy seizures, memory and cognition and our proprietary pre-clinical combinatorial lipid program. Amarin has its primary stock market listing in the U.S. on NASDAQ ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"), respectively. For press releases and other corporate information, visit the Amarin website at www.amarincorp.com. Information on our website does not form part of this press release. Contacts: Amarin +44 (0) 207 907 2442 Rick Stewart Chief Executive Officer Alan Cooke President & Chief Financial Officer investor.relations@amarincorp.com Investors: Lippert/Heilshorn & Associates, Inc. +1 212 838 3777 Kim Golodetz Anne Marie Fields Media: Powerscourt +44 (0) 207 250 1446 Rory Godson Victoria Brough Davy Fergal Meegan +353 (0) 1 679 6363 This information is provided by RNS The company news service from the London Stock Exchange END LISUAVVRBSRBOAR
1 Year Amarin Chart |
1 Month Amarin Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions